Fisetin: Senolytic, Longevity & Cognitive Function — Evidence Review
⚡ 60-Second Summary
Fisetin (3,3′,4′,7-tetrahydroxyflavone) is a naturally occurring flavonoid found in strawberries, apples, mangoes, and persimmons — with the highest concentration in strawberries (~160 μg/g). It has emerged as a leading candidate senolytic compound (selectively kills senescent 'zombie' cells) based on strong preclinical evidence and a few early human trials.
Best-evidenced uses: Senolytic activity in human trials (Mayo Clinic Phase 1 trial showed senescent cell biomarker reduction in older adults); neuroprotection and cognitive function (multiple animal studies; human trial in Alzheimer's disease ongoing); anti-inflammatory; antioxidant. Most of the strongest evidence remains from animal models — human clinical trial evidence is early but promising.
Practical note: Fisetin is typically used intermittently ('pulsed' dosing) rather than daily, following the senolytic protocol from the Mayo Clinic research group — 20 mg/kg body weight for 2 consecutive days per month. Daily use is also practiced for general antioxidant/anti-inflammatory effects (100–500 mg/day). The intermittent high-dose protocol is the most scientifically grounded approach for senolytic purposes.
What is Fisetin?
Fisetin's senolytic mechanism involves activating apoptosis specifically in senescent cells through inhibition of pro-survival pathways (PI3K/Akt/mTOR, Bcl-2/BCL-xL). Senescent cells accumulate with age and secrete pro-inflammatory cytokines (the 'SASP' — Senescence-Associated Secretory Phenotype). Clearing them reduces chronic inflammation and may slow aging-related tissue dysfunction. Fisetin also activates sirtuins (SIRT1, SIRT3), inhibits mTOR, and activates AMPK — longevity-associated pathways.
Fisetin was identified in the 1960s as a plant pigment but attracted little research attention until the 2000s. A landmark 2018 EBioMedicine study (Yousefzadeh et al.) showed fisetin was the most potent senolytic among 10 compounds tested in mice — extending healthy lifespan by ~10% when given to old mice. The Mayo Clinic initiated the first human senolytic trial (SToFIs) in 2019. Multiple follow-on trials are now underway.
Evidence-based benefits
1. Senolytic activity (human trial evidence)
Mayo Clinic Phase 1 SToFIs trial (2022, n=40 older adults) showed fisetin 20 mg/kg/day for 2 days reduced markers of senescent T-cells and adipose tissue senescence. This is preliminary but the first direct human evidence for fisetin's senolytic activity.
2. Cognitive function
Multiple animal models show fisetin reverses cognitive decline in Alzheimer's and aging models. A human clinical trial in MCI and Alzheimer's disease (MIDAS trial) is ongoing. Human evidence is very limited currently.
3. Anti-inflammatory and antioxidant
In vitro and animal studies show fisetin inhibits NF-κB, reduces SASP cytokines (IL-6, IL-8, MMP), activates Nrf2, and scavenges free radicals. These effects underlie both its anti-aging and neuroprotective properties.
Supplement forms compared
| Form | Typical dose / Bioavailability | Best for | Notes |
|---|---|---|---|
| Fisetin capsules (powder) | 100–500 mg/day (daily use) or 20 mg/kg for 2 days/month (senolytic protocol) | Anti-inflammatory, antioxidant, longevity | Most common form. Take with fat for better absorption. |
| Fisetin in liposomal delivery | 100–300 mg/day | Enhanced bioavailability | Improved absorption of fat-soluble flavonoid; fewer clinical studies. |
| Dietary fisetin (strawberries) | Much lower amounts | General polyphenol intake | ~1.5 mg fisetin per 100g fresh strawberries — far below supplement doses. |
How much should you take?
- General antioxidant/anti-inflammatory: 100–500 mg/day with fat-containing meal
- Senolytic protocol (from Mayo research): 20 mg/kg body weight/day for 2 consecutive days per month (e.g., 1,500 mg/day for 75 kg person, 2 days on, rest of month off)
Fisetin is fat-soluble — absorption improves with a fat-containing meal. The intermittent senolytic dosing protocol should not be confused with daily antioxidant use — these are different rationales with different doses. Given the early stage of human evidence, conservative daily doses (100–500 mg) are reasonable for antioxidant purposes; senolytic dosing should be discussed with a physician.
Safety and side effects
Common side effects
- Well-tolerated in all published human studies; no significant adverse events reported
- Theoretical interactions based on CYP3A4 and CYP2C8 inhibition in vitro at high doses
- Very limited long-term human safety data — most research is <12 months
Serious risks
Fisetin appears very safe in the limited human trials published to date. Its mechanism of selectively inducing apoptosis in senescent cells has not produced off-target toxicity in studies. However, long-term safety data in humans is minimal. People with cancer who might have concerns about apoptotic pathway modulation should discuss with their oncologist.
Drug and nutrient interactions
- Anticoagulants — fisetin has mild antiplatelet effects in vitro; theoretical additive bleeding effect; monitor
- Immunosuppressants — senolytic immune modulation is unstudied in transplant patients; consult physician
- CYP3A4 substrates — in vitro inhibition at high doses; clinical significance at supplement doses is unknown
Check our free interaction checker for additional combinations.
Who might benefit — and who should use caution
| Most likely to benefit | Use with caution or seek guidance |
|---|---|
| People interested in longevity research and evidence-based anti-aging interventions | People with cancer who have apoptotic pathway concerns — consult oncologist |
| Older adults (65+) concerned about cellular senescence and chronic inflammation | Pregnant or breastfeeding women — no safety data in these populations |
| Those with interest in the intermittent senolytic protocol from Mayo Clinic research | People expecting immediate dramatic anti-aging effects — current evidence is early-stage |
| Individuals seeking natural antioxidant and anti-inflammatory supplementation |
Frequently asked questions
What is a senolytic?
A senolytic is a compound that selectively induces apoptosis (programmed cell death) in senescent cells — old, damaged cells that have stopped dividing but resist normal cell death. These 'zombie cells' accumulate with age and secrete pro-inflammatory molecules (SASP) that damage neighboring tissues. Clearing them is proposed as a mechanism to slow aging and reduce chronic disease. Fisetin is one of the most studied natural senolytics.
How does the fisetin senolytic protocol work?
Based on the Mayo Clinic SToFIs trial design, the senolytic protocol uses high doses (20 mg/kg/day) for two consecutive days per month, followed by 28 days off. The logic is that senolytics need only brief exposure to trigger apoptosis in senescent cells — sustained high doses are not needed and may be wasteful or carry unnecessary risk.
Is the evidence for fisetin strong enough to recommend it?
Preclinical evidence in animal models is very strong. Human evidence is early: one Phase 1 trial showed senescent cell biomarker reduction; Alzheimer's trials are ongoing. For general antioxidant and anti-inflammatory use at 100–500 mg/day, the risk-benefit ratio is favorable given fisetin's excellent safety profile. For senolytic protocols, the evidence is promising but preliminary.
How does fisetin compare to quercetin?
Quercetin is also a studied senolytic (used in the first human dasatinib+quercetin trial). Fisetin was found to be 5× more potent than quercetin as a senolytic in the 2018 EBioMedicine mouse study. Both are flavonoids with similar mechanisms. Fisetin is emerging as the preferred natural senolytic candidate, though more human trial data is needed.
Can I get enough fisetin from strawberries?
No — strawberries contain approximately 160 μg fisetin per gram, meaning you'd need ~6 kg (13 lbs) of strawberries daily to reach even 1,000 mg fisetin. Supplementation is required for any therapeutic dose. Dietary strawberry consumption provides meaningful but much lower fisetin amounts — contributing to general polyphenol intake alongside other nutrients.
Related ingredients
Quercetin
Related senolytic flavonoid with longer clinical research history; often combined with fisetin.
Spermidine
Another longevity compound with autophagy-activating mechanism distinct from senolytics.
Resveratrol
Sirtuin-activating longevity compound with cardiovascular and cancer prevention evidence.
Disclaimer: This information is for educational purposes only and should not replace medical advice. Always consult a qualified healthcare provider before starting any supplement, especially if you have a medical condition, are pregnant, or take prescription medications. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.